The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00270101|
Recruitment Status : Completed
First Posted : December 26, 2005
Last Update Posted : May 18, 2011
|Condition or disease||Intervention/treatment||Phase|
|Anemia Multiple Myeloma||Drug: epoetin alfa||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||156 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Placebo-Controlled Study on the Effect of r-huEPO in Patients With Multiple Myeloma Followed by an Open-Label Extension|
|Study Start Date :||January 1995|
|Actual Study Completion Date :||September 1996|
U.S. FDA Resources
- Proportion of patients requiring transfusion and number of units transfused relative to whether or not patients received transfusion(s) before the study.
- Increase in hemoglobin, hematocrit, developing red blood cells in the blood; Changes in quality-of-life; Safety evaluations (incidence of adverse events, laboratory tests, and vital signs) including changes in underlying multiple myeloma.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00270101
|Study Director:||Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|